We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

Back to rankings

1 hedge funds and large institutions have $1K invested in Osiris Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 57 → 1 (-56)

100% less capital invested

Capital invested by funds: $130M → $1K (-$130M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 56

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-56
Holders Change %
-98.25%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
56
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AAM
Alpine Associates Management
Florida
-$23.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$15.6M
3
GF
Gabelli Funds
New York
-$11M
4
Renaissance Technologies
Renaissance Technologies
New York
-$7.54M
5
Millennium Management
Millennium Management
New York
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
FGAM
1
Financial Gravity Asset Management
Texas
$1K -$171 -9 -14%
AAM
2
Alpine Associates Management
Florida
– -$23.4M -1,233,589 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$15.6M -821,457 Closed
GF
4
Gabelli Funds
New York
– -$11M -578,517 Closed
Renaissance Technologies
5
Renaissance Technologies
New York
– -$7.54M -396,605 Closed
Millennium Management
6
Millennium Management
New York
– -$6.42M -337,701 Closed
CCM
7
Cloverdale Capital Management
Texas
– -$6.17M -324,722 Closed
Goldman Sachs
8
Goldman Sachs
New York
– -$5.17M -272,227 Closed
WIC
9
Water Island Capital
New York
– -$4.89M -257,485 Closed
BCM
10
Beryl Capital Management
California
– -$4.18M -220,189 Closed
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
– -$3.33M -175,223 Closed
Geode Capital Management
12
Geode Capital Management
Massachusetts
– -$3.05M -160,461 Closed
VI
13
Versor Investments
New York
– -$2.16M -113,905 Closed
CS
14
Credit Suisse
Switzerland
– -$2.11M -111,102 Closed
Northern Trust
15
Northern Trust
Illinois
– -$2.08M -109,732 Closed
WRBC
16
W.R. Berkley Corp
Connecticut
– -$2.08M -109,601 Closed
QI
17
QS Investors
New York
– -$2.01M -105,759 Closed
DAM
18
DLD Asset Management
New York
– -$1.9M -100,000 Closed
Deutsche Bank
19
Deutsche Bank
Germany
– -$1.88M -98,700 Closed
HIM
20
Hillsdale Investment Management
Ontario, Canada
– -$1.77M -92,941 Closed
GCIA
21
Gabelli & Co Investment Advisers
New York
– -$1.74M -91,411 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$1.68M -88,142 Closed
BlackRock
23
BlackRock
New York
– -$1.66M -87,321 Closed
Bank of America
24
Bank of America
North Carolina
– -$1.58M -83,046 Closed
Barclays
25
Barclays
United Kingdom
– -$1.57M -82,690 Closed
1
2 3

OSIR Hedge Fund Activity: Q2 2019 in Review

1 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q2 2019, worth a combined $1K — down 100% from $130M a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of OSIR and 0 opened new positions — a net loss of 56 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Alpine Associates Management, exiting entirely with an estimated $23.4M sold.

  • 1 institutional investor held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q2 2019, down from 57 in Q1 2019.
  • Funds reported $1K of Osiris Therapeutics, Inc. Common Stock stock for Q2 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q2 2019 and 56 closed out, a net change of -56 holders.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q2 2019 was Alpine Associates Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q2 2019.